Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2011

Inhalt (35 Artikel)

Review

Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies

Sihua Peng, Bingjian Lü, Wenjing Ruan, Yimin Zhu, Hongqiang Sheng, Maode Lai

Preclinical study

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

Kirsten Vang Nielsen, Bent Ejlertsen, Sven Müller, Susanne Møller, Birgitte B. Rasmussen, Eva Balslev, Anne-Vibeke Lænkholm, Peer Christiansen, Henning T. Mouridsen

Preclinical study

PALB2 analysis in BRCA2-like families

M. A. Adank, S. E. van Mil, J. J. P. Gille, Q. Waisfisz, H. Meijers-Heijboer

Preclinical study

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

François Bertucci, Nathalie Borie, Henri Roche, Thomas Bachelot, Jean-Marc Le Doussal, Gaëtan Macgrogan, Stéphane Debono, Agnès Martinec, Isabelle Treilleux, Pascal Finetti, Benjamin Esterni, Jean-Marc Extra, Jean Geneve, Fabienne Hermitte, Christian Chabannon, Jocelyne Jacquemier, Anne-Laure Martin, Michel Longy, Dominique Maraninchi, Vincent Fert, Daniel Birnbaum, Patrice Viens

Preclinical study

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

Yesim Gökmen-Polar, Rachel A. Toroni, Barbara A. Hocevar, Sunil Badve, Qianqian Zhao, Changyu Shen, Elizabeth Bruckheimer, Michael S. Kinch, Kathy D. Miller

Preclinical study

The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells

Paul T. R. Thiruchelvam, Chun-Fui Lai, Hui Hua, Ross S. Thomas, Antoni Hurtado, William Hudson, Andrew R. Bayly, Fiona J. Kyle, Manikandan Periyasamy, Andrew Photiou, Alan C. Spivey, Eric A. Ortlund, Richard J. Whitby, Jason S. Carroll, R. Charles Coombes, Laki Buluwela, Simak Ali

Preclinical study

Three-dimensional collagen represses cyclin E1 via β1 integrin in invasive breast cancer cells

Yuehan Wu, Xun Guo, Yekaterina Brandt, Helen J. Hathaway, Rebecca S. Hartley

Preclinical study

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer

Mohammed A. Aleskandarany, Emad A. Rakha, Mohamed A. Ahmed, Desmond G. Powe, Ian O. Ellis, Andrew R. Green

Preclinical study

Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling

Christoforos G. Thomas, Anders Strom, Karolina Lindberg, Jan-Ake Gustafsson

Clinical Trial

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

R. Coleman, E. Woodward, J. Brown, D. Cameron, R. Bell, D. Dodwell, M. Keane, M. Gil, C. Davies, R. Burkinshaw, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee, H. Thorpe

Clinical trial

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

Kerri M. Winters-Stone, Jessica Dobek, Lillian Nail, Jill A. Bennett, Michael C. Leo, Arpana Naik, Anna Schwartz

Erratum

Erratum to: Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

Kerri M. Winters-Stone, Jessica Dobek, Lillian Nail, Jill A. Bennett, Michael C. Leo, Arpana Naik, Anna Schwartz

Clinical Trial

Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients

I. Gounaris, E. Provenzano, A. L. Vallier, L. Hiller, M. Iddawela, S. Hilborne, K. Taylor, P. Britton, H. M. Earl, R. Sinnatamby

Epidemiology

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

Melinda L. Telli, Ellen T. Chang, Allison W. Kurian, Theresa H. M. Keegan, Laura A. McClure, Daphne Lichtensztajn, James M. Ford, Scarlett L. Gomez

Epidemiology

Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women

E. Comen, L. Balistreri, M. Gönen, A. Dutra-Clarke, M. Fazio, J. Vijai, Z. Stadler, N. Kauff, T. Kirchhoff, C. Hudis, K. Offit, M. Robson

Epidemiology

Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel

Yael Laitman, Roni Tsipora Borsthein, Dominique Stoppa-Lyonnet, Efrat Dagan, Laurent Castera, Maud Goislard, Ruth Gershoni-Baruch, Hadassah Goldberg, Bella Kaufman, Noa Ben-Baruch, Jamal Zidan, Taiseer Maray, Lior Soussan-Gutman, Eitan Friedman

Epidemiology

Periodontal disease may associate with breast cancer

Birgitta Söder, Maha Yakob, Jukka H. Meurman, Leif C. Andersson, Björn Klinge, Per-Östen Söder

Epidemiology

Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators

Hatef Darabi, Kamila Czene, Sara Wedrén, Yuqing Li, Jianjun Liu, Per Hall, Keith Humphreys

Epidemiology

Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI)

Maria Pisu, Andres Azuero, Karen Meneses, Jeffrey Burkhardt, Patrick McNees

Epidemiology

The role of polymorphisms in circadian pathway genes in breast tumorigenesis

Hongji Dai, Lina Zhang, Mingli Cao, Fengju Song, Hong Zheng, Xiaoling Zhu, Qingyi Wei, Wei Zhang, Kexin Chen

Epidemiology

Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer

Ruth E. Patterson, Nazmus Saquib, Loki Natarajan, Cheryl L. Rock, Barbara A. Parker, Cynthia A. Thomson, John P. Pierce

Epidemiology

Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk

Rongxi Yang, Michelle Dick, Frederik Marme, Andreas Schneeweiss, Anne Langheinz, Kari Hemminki, Christian Sutter, Peter Bugert, Barbara Wappenschmidt, Raymonda Varon, Sarah Schott, Bernhard H. F. Weber, Dieter Niederacher, Norbert Arnold, Alfons Meindl, Claus R. Bartram, Rita K. Schmutzler, Heiko Müller, Volker Arndt, Hermann Brenner, Christof Sohn, Barbara Burwinkel

Epidemiology

Circulating levels of inflammatory markers and mammographic density among postmenopausal women

Katherine W. Reeves, Joel L. Weissfeld, Francesmary Modugno, Brenda Diergaarde

Letter to the Editor

VEGF 936C>T polymorphism and breast cancer risk: evidence needed further clarification

Liu Liu, Fu-Zhou Hua, Jia-Qing Cao, Pei-Qian Zhu

Letter to the Editor

Soy consumption and breast cancer risk: four recent meta-analyses

Chun Zhang, Jian-Ping Li, Ping Zhou

Letter to the Editor

Green tea consumption and breast cancer risk: three recent meta-analyses

Ping Zhou, Jian-Ping Li, Chun Zhang

Invited commentary

Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?

Kazuhiro Araki, Mark Pegram

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.